Novel Anemia Therapies in CKD: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

[1]  Ashutosh Kumar Singh,et al.  The ASCEND-NHQ trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis-dependent chronic kidney disease. , 2023, Kidney international.

[2]  Haiying Song,et al.  Suppression of thyroid profile during roxadustat treatment in chronic kidney disease patients. , 2023, Nephrology, Dialysis and Transplantation.

[3]  Ashutosh Kumar Singh,et al.  Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply. , 2022, New England Journal of Medicine.

[4]  Ashutosh Kumar Singh,et al.  Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients , 2022, Clinical journal of the American Society of Nephrology : CJASN.

[5]  D. Agrawal,et al.  Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND) , 2022, American Journal of Nephrology.

[6]  J. Bhatt,et al.  Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D) , 2022, American Journal of Nephrology.

[7]  Ashutosh Kumar Singh,et al.  Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients , 2022, JAMA internal medicine.

[8]  A. Joharapurkar,et al.  Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state , 2022, Current research in pharmacology and drug discovery.

[9]  A. Rastogi,et al.  Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study , 2022, Journal of the American Society of Nephrology : JASN.

[10]  Q. Nguyen,et al.  Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin , 2022, Kidney international reports.

[11]  S. Solomon,et al.  Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. , 2021, The New England journal of medicine.

[12]  S. Solomon,et al.  Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. , 2021, The New England journal of medicine.

[13]  C. Esposito,et al.  Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES) , 2021, Advances in Therapy.

[14]  T. Akizawa,et al.  Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial , 2021, American Journal of Nephrology.

[15]  T. Akizawa,et al.  Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study , 2021, American Journal of Nephrology.

[16]  C. Esposito,et al.  Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies , 2021, Advances in Therapy.

[17]  Zhanjun Jia,et al.  Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS , 2021, JCI insight.

[18]  M. Nangaku,et al.  Two long‐term phase 3 studies of enarodustat (JTZ‐951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND‐Long and HD‐Long studies , 2021, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[19]  W. Winkelmayer,et al.  Cardiovascular Safety of Roxadustat in CKD Anemia: A Fig Leaf Named Noninferiority. , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[20]  L. Szczech,et al.  Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non–Dialysis-Dependent CKD , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[21]  Z. Massy,et al.  Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia , 2021, Journal of the American Society of Nephrology : JASN.

[22]  M. Nangaku,et al.  A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study , 2021, Kidney Diseases.

[23]  T. Akizawa,et al.  Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis , 2021, Kidney international reports.

[24]  B. Baradaran,et al.  Up-down regulation of HIF-1α in cancer progression. , 2021, Gene.

[25]  M. Nangaku,et al.  A phase 3, open‐label, single‐arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis‐stimulating agents , 2021, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[26]  J. Barratt,et al.  Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES) , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  M. Nangaku,et al.  A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study , 2021, Kidney international reports.

[28]  M. Nangaku,et al.  Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients , 2021, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[29]  Kimberly A. Walters,et al.  Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. , 2021, The New England journal of medicine.

[30]  Kimberly A. Walters,et al.  Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. , 2021, The New England journal of medicine.

[31]  M. Burmakin,et al.  Pharmacological HIF‐PHD inhibition reduces renovascular resistance and increases glomerular filtration by stimulating nitric oxide generation , 2021, Acta physiologica.

[32]  M. Nangaku,et al.  Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD , 2021, Journal of the American Society of Nephrology : JASN.

[33]  M. Iwasaki,et al.  Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD , 2021, Kidney international reports.

[34]  D. Tarng,et al.  Controversies in Optimal Anemia Management: Conclusions from a Kidney Disease Improving Global Outcomes (KDIGO) Conference. , 2021, Kidney international.

[35]  L. Szczech,et al.  A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study , 2021, Kidney international reports.

[36]  A. Agarwal.  Iron metabolism and management: focus on chronic kidney disease. , 2021, Kidney international supplements.

[37]  V. Haase.  Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. , 2021, Kidney international supplements.

[38]  T. Ganz,et al.  Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone. , 2021, Kidney international.

[39]  M. Emoto,et al.  Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis , 2021, BMC Nephrology.

[40]  M. Nangaku,et al.  Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  C. Esposito,et al.  Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS) , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[42]  L. Szczech,et al.  Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[43]  Z. Massy,et al.  Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[44]  P. Ponikowski,et al.  Effect of dapagliflozin on anaemia in DAPA‐HF , 2021, European journal of heart failure.

[45]  S. Fishbane,et al.  Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. , 2021, Journal of the American Society of Nephrology : JASN.

[46]  M. Nangaku,et al.  Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial , 2021, American Journal of Nephrology.

[47]  T. Akizawa,et al.  Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single‐arm, phase 3 study , 2021, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[48]  N. Kashihara,et al.  Roxadustat and thyroid-stimulating hormone suppression , 2021, Clinical kidney journal.

[49]  L. Szczech,et al.  Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis , 2020, Kidney international reports.

[50]  M. Nangaku,et al.  Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open‐label study in Japan , 2020, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[51]  L. Szczech,et al.  Roxadustat for CKD-related Anemia in Non-dialysis Patients , 2020, Kidney international reports.

[52]  Yusuke Suzuki,et al.  Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF‐PH inhibitors , 2020, Nephrology.

[53]  A. Levin,et al.  Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. , 2020, The lancet. Diabetes & endocrinology.

[54]  J. Craig,et al.  Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease , 2020, Cochrane Database of Systematic Reviews.

[55]  D. Wheeler,et al.  Correction of anemia by dapagliflozin in patients with type 2 diabetes. , 2020, Journal of diabetes and its complications.

[56]  M. Nangaku,et al.  Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[57]  M. Nangaku,et al.  Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[58]  D. DeMets,et al.  Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF , 2020, Circulation.

[59]  T. Akizawa,et al.  A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis , 2020, Nephron.

[60]  M. Iwasaki,et al.  Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan. , 2020, Journal of the American Society of Nephrology : JASN.

[61]  K. Mahaffey,et al.  Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. , 2020, Kidney international.

[62]  Tetsuhiro Tanaka,et al.  Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease. , 2020, Current opinion in nephrology and hypertension.

[63]  G. Dimitriadis,et al.  Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes , 2020, American Journal of Nephrology.

[64]  P. Dandona,et al.  Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis. , 2020, The Journal of clinical endocrinology and metabolism.

[65]  K. Eckardt,et al.  Role of oxygen and the HIF-pathway. , 2020, Cellular signalling.

[66]  M. Woodward,et al.  Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes. , 2020, JACC. Heart failure.

[67]  T. Akizawa,et al.  Oral roxadustat three times weekly in ESA‐naïve and ESA‐converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies , 2019, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[68]  T. Maruyama,et al.  Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease , 2019, Diabetes technology & therapeutics.

[69]  P. Ratcliffe,et al.  Mechanisms of hypoxia signalling: new implications for nephrology , 2019, Nature Reviews Nephrology.

[70]  N. Gupta,et al.  The stimulation of thrombosis by hypoxia. , 2019, Thrombosis research.

[71]  T. Akizawa,et al.  Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐Label Study , 2019, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[72]  L. Szczech,et al.  Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. , 2019, The New England journal of medicine.

[73]  L. Szczech,et al.  Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. , 2019, The New England journal of medicine.

[74]  R. Lai,et al.  Iron-deficiency and estrogen are associated with ischemic stroke by up-regulating transferrin to induce hypercoagulability , 2019, bioRxiv.

[75]  J. McMurray,et al.  Intravenous Iron in Patients Undergoing Maintenance Hemodialysis , 2019, The New England journal of medicine.

[76]  M. Nangaku,et al.  A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial , 2019, American Journal of Nephrology.

[77]  I. Macdougall,et al.  Effects of Molidustat in the Treatment of Anemia in CKD. , 2018, Clinical journal of the American Society of Nephrology : CJASN.

[78]  Fu-Li Lv,et al.  Effects of HIF-1α on diabetic retinopathy angiogenesis and VEGF expression. , 2018, European review for medical and pharmacological sciences.

[79]  I. Macdougall,et al.  HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics , 2018, Pediatric Nephrology.

[80]  J. Lepore,et al.  Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis , 2018, Clinical kidney journal.

[81]  B. Zinman,et al.  How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial , 2017, Diabetes Care.

[82]  Ralph B. D'Agostino,et al.  Challenges in the Design and Interpretation of Noninferiority Trials , 2017, The New England journal of medicine.

[83]  Tetsuhiro Tanaka,et al.  Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. , 2017, Kidney international.

[84]  J. Wish,et al.  Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[85]  J. Brugarolas,et al.  Hypoxia-inducible factor 1α activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver , 2017, The Journal of Biological Chemistry.

[86]  E. Ferrannini,et al.  Renal Handling of Ketones in Response to Sodium–Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes , 2017, Diabetes Care.

[87]  M. Nangaku,et al.  Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects , 2016, American Journal of Nephrology.

[88]  V. Haase,et al.  Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. , 2016, Kidney international.

[89]  E. Cummins,et al.  Hypoxia-dependent regulation of inflammatory pathways in immune cells. , 2016, The Journal of clinical investigation.

[90]  S. Hemmerich,et al.  Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[91]  A. Rastogi,et al.  Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. , 2016, Journal of the American Society of Nephrology : JASN.

[92]  S. Hemmerich,et al.  Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients. , 2016, Journal of the American Society of Nephrology : JASN.

[93]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[94]  S. Hemmerich,et al.  Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[95]  M. Rosen,et al.  Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation‐induced anaemia in rats , 2015, British journal of pharmacology.

[96]  J. Keldenich,et al.  Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85-3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects , 2014, PloS one.

[97]  M. Cappellini,et al.  A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[98]  D. de Zeeuw,et al.  Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes , 2013, Diabetes, obesity & metabolism.

[99]  V. Campese,et al.  Is Lipid Management Effective for All Stages of CKD , 2013, Blood Purification.

[100]  Herbert Y. Lin,et al.  Mechanisms of anemia in CKD. , 2012, Journal of the American Society of Nephrology : JASN.

[101]  K. Duffy,et al.  Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury. , 2012, American journal of physiology. Renal physiology.

[102]  Jia Yu,et al.  Hypoxia-inducible factor-1 (HIF-1) promotes LDL and VLDL uptake through inducing VLDLR under hypoxia. , 2012, The Biochemical journal.

[103]  A. Neu,et al.  Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS , 2010, Pediatric Nephrology.

[104]  S. Solomon,et al.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.

[105]  V. Haase.  The VHL tumor suppressor: master regulator of HIF. , 2009, Current pharmaceutical design.

[106]  V. Haase.  Pathophysiological Consequences of HIF Activation , 2009, Annals of the New York Academy of Sciences.

[107]  E. Rankin,et al.  Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. , 2007, The Journal of clinical investigation.

[108]  F. Schaefer,et al.  Increased injection pain with darbepoetin-α compared to epoetin-β in paediatric dialysis patients , 2006 .

[109]  H. Burger,et al.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.

[110]  Huiman Barnhart,et al.  Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.

[111]  Gaël Nicolas,et al.  The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. , 2002, The Journal of clinical investigation.

[112]  S. McKnight,et al.  A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.

[113]  A R Nissenson,et al.  The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. , 1998, The New England journal of medicine.

[114]  OUP accepted manuscript , 2021, Nephrology, Dialysis and Transplantation.

[115]  C. Grimm,et al.  The Role of Hypoxia, Hypoxia-Inducible Factor (HIF), and VEGF in Retinal Angiomatous Proliferation. , 2018, Advances in experimental medicine and biology.

[116]  J. Adamson,et al.  KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease , 2012 .

[117]  Peter Hill,et al.  Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. , 2008, Journal of the American Society of Nephrology : JASN.